Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

Abstract

The dal-VESSEL trial has established the tolerability and safety of CETP-inhibition with dalcetrapib in patients with or at risk of CHD. Dalcetrapib reduced CETP activity and increased HDL-C levels without affecting NO-dependent endothelial function, blood pressure, or markers of inflammation and oxidative stress.

The dal-OUTCOMES trial (NCT00658515) will show whether dalcetrapib improves outcomes in spite of a lack of effect on endothelial function.

Full Text

• DOI - European heart journal (DOI)
• Swets Information Services - full-text online
• Ovid Technologies, Inc. - full-text online
• OhioLINK Electronic Journal Center - full-text online
• HighWire Press - full-text online
• EBSCO - full-text online

Subjects

• Aged
• Anticholesteremic Agents
• Biological Markers
• Blood Flow Velocity
• Blood Pressure
• Brachial Artery
• Cholesterol Ester Transfer Proteins
• Cholesterol, HDL
• Cholesterol, LDL
• Coronary Disease
• Double-Blind Method
• Endothelium, Vascular
• Female
• Humans
• Hypercholesterolemia
• Male
• Middle Aged
• Sulfhydryl Compounds
• Treatment Outcome
• Triglycerides
• Vasodilation

Similar articles

• Effects of dalcetrapib in patients with a recent acute coronary syndrome. (2012-11-05)
• Therapeutic targets to raise HDL in patients at risk or with coronary artery disease. (2012-12-24)
• Safety of CETP inhibition. (2012-09-27)
• An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. (2012-08-08)
• Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? (2011-11-23)
• Cholesteryl Ester Transfer Protein in Patients with Rheumatoid Arthritis. (2013-05-15)
• Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective. (2013-05-09)
• Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? (2013-05-09)
• Review of the quantitative analysis of cholesteryl ester transfer protein inhibitors. (2013-05-07)

Authors

• Thomas F Lüscher
• Stefano Taddei
• Juan-Carlos Kaski
• J Wouter Jukema
• David Kallend
• Thomas Münzel
• John J P Kastelein
• John E Deanfield

Publication date

2012-04-04

Journal

Journal topics

• Cardiology

Language

Eng.

Copyright

European heart journal

Department of Cardiology, Cardiovascular Centre, University of Zurich, 8091 Zurich, Switzerland. cardiotfl [at] gmx.ch

Release reference

Eur Heart J. 2012 Apr;33(7):857-65

Related books

• Books of Anticholesteremic Agents
• Books of Biological Markers
• Books of Blood Flow Velocity
• Books of Blood Pressure
• Books of Brachial Artery
• Books of Cardiology
• Books of Cholesterol Ester Transfer Proteins
• Books of Cholesterol, HDL
• Books of Cholesterol, LDL
• Books of Coronary Disease
• Books of Double-Blind Method
• Books of Endothelium, Vascular
• Books of Hypercholesterolemia
• Books of Sulfhydryl Compounds
• Books of Treatment Outcome
• Books of Triglycerides
• Books of Vasodilation